Revenue distribution by sectors:

• Food: approx. 40%
• Health: approx. 30%
• Materials Science: approx. 30%

TOP 3 markets:

• USA: approx. 25%
• China: approx. 20%
• Germany: approx. 15%

DSM-Firmenich AG generates its revenues mainly from three core areas: food, health, and materials science. This diversification enables the company to hedge against market fluctuations and benefit from various growth opportunities.

The USA, China, and Germany are the largest markets for DSM-Firmenich, with the USA having the largest share of revenue. This reflects the strong presence and demand in these regions, especially in the food and health sectors.

Production Sites: Worldwide, with a focus on Europe, North America, and Asia.

DSM-Firmenich AG is a globally operating company that operates production facilities in various regions of the world. The focus is on Europe, North America, and Asia, which represents a strategic distribution to efficiently serve the demand in these markets.

In Europe, the Netherlands is a significant location, while in North America and Asia, several production sites exist to strengthen regional presence and leverage logistical advantages. This geographical diversification enables DSM-Firmenich to flexibly respond to market changes and optimize supply chains.

Revenue Growth: Estimated 10% annually (2025)

Focus on Sustainable Innovations: DSM-Firmenich AG places a strong emphasis on sustainable innovations to secure future growth. The company invests in research and development to develop environmentally friendly products that meet the increasing demands for sustainability.

Expansion into Emerging Markets: Another strategic focus is on expanding into emerging markets. DSM-Firmenich plans to strengthen its presence in these regions to benefit from the growing demand for high-quality food and health solutions.

Mergers and Acquisitions: The company pursues an active strategy of mergers and acquisitions to strengthen its market position and integrate new technologies and product lines. This allows DSM-Firmenich to leverage synergies and increase its innovation capabilities.

These strategic measures are intended to enable the company to expand its market leadership and achieve long-term profitable growth.

Main raw materials: Vitamins, enzymes, flavors, fragrances

Countries of origin: China, USA, Brazil, Germany

DSM-Firmenich AG, a leading company in the food and fragrance industry, imports a variety of raw materials that are essential for the production of their products. Vitamins and enzymes, which are often used in many of their dietary supplements and feed additives, are frequently sourced from China, known as one of the largest producers of these raw materials.

Flavors and fragrances, important for the perfume and food industry, are often sourced from the USA and Germany, where there are specialized manufacturers. Brazil is also an important supplier, especially for natural raw materials and flavors derived from the country's diverse flora.

This global sourcing enables DSM-Firmenich to offer high-quality products at competitive prices while also focusing on sustainability and innovation.

Market share in the industry: 12% (2024)
R&D investments: 7.5% of revenue (2024)
EBITDA margin: 18% (2024)

DSM-Firmenich AG has gained a significant competitive advantage through a strong position in the specialty chemicals and flavors industry. With a market share of 12%, the company is one of the leading providers in this sector.

A key factor for this competitive advantage is the high investment in research and development, amounting to 7.5% of revenue. These investments enable DSM-Firmenich to continuously develop innovative products and differentiate itself from the competition.

Additionally, the company maintains a solid EBITDA margin of 18%, indicating efficient operations and strong pricing strategies. These financial metrics, combined with a wide range of products and a global presence, significantly strengthen the competitive advantage of DSM-Firmenich AG.

Institutional Investor Share: approximately 65% (estimated for 2025 based on historical data)

Insider Buys/Sells: No significant transactions reported (as of 2025)

The institutional investor share at DSM-Firmenich AG traditionally falls within the range of 60-70%, indicating the confidence of large investors in the company's stability and growth potential. These investors include pension funds, investment funds, and other major financial institutions.

No significant insider transactions were reported for the year 2025. This could suggest that the management and other insiders currently do not anticipate any significant changes in the company's valuation or that they are satisfied with the current corporate strategy.

Market share DSM-Firmenich AG: 12% (estimated for 2025)

Top competitors and their market shares:

1. Givaudan SA: 18%
2. International Flavors & Fragrances Inc. (IFF): 16%
3. Symrise AG: 14%
4. DSM-Firmenich AG: 12%
5. Kerry Group: 10%
6. Takasago International Corporation: 8%
7. Robertet Group: 6%
8. Mane SA: 5%

Moat DSM-Firmenich AG:

DSM-Firmenich AG has a significant moat due to its strong position in the combination of flavors and fragrances as well as nutrition. The merger of DSM and Firmenich has led to a unique synergy that enables the company to offer comprehensive solutions applicable in both the food and cosmetics industries.

Compared to competitors, DSM-Firmenich has an advantage through the integration of research and development and a wide range of products. Particularly, their innovation capabilities and ability to offer customized solutions strengthen their market position.

However, other companies like Givaudan and IFF also have strong moats, especially through their established global networks and long-standing customer relationships. These companies also heavily invest in research and development to maintain and expand their market positions.

Overall, DSM-Firmenich possesses a solid moat, yet it is challenged by strong competition and their own strategic advantages.

Revenue Growth: 10% (2024) Profit Growth: 8% (2024) Research & Development (R&D) Expenses: 5% of revenue (2024)

DSM-Firmenich AG recorded solid revenue growth of 10% in 2024, driven by strong demand in its core segments. The company is well positioned to benefit from synergies and an expanded product range following the merger of DSM and Firmenich.

The R&D expenses, accounting for 5% of revenue, highlight the company's commitment to innovation and developing new products, which can secure long-term competitive advantages. This is particularly crucial in the industry where DSM-Firmenich operates, as continuous innovation is vital for maintaining market leadership.

Additionally, the company achieved a profit growth of 8%, indicating an efficient cost structure and successful integration of the two business units. These factors suggest that DSM-Firmenich is well positioned to achieve further growth in the coming years.

Overall, DSM-Firmenich AG could be an attractive investment, especially for investors focusing on long-term growth and innovation.

Dividend yield: 2.5% (2025, estimated)
Dividend history: Steady payout over the last 5 years

DSM-Firmenich AG has been paying out a consistent dividend in recent years, indicating a reliable dividend policy. The estimated dividend yield for 2025 is around 2.5%, which can be considered stable compared to other companies in the industry.

The company has a solid financial foundation and pursues a strategy that supports both growth and returning capital to shareholders. This suggests that DSM-Firmenich AG should also be able to reliably distribute dividends in the future.